Metraipolis › archive › dc_109fe18092ef

Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade — Europe PMC PMID:41291775

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41291775
DOI
10.1186/s13046-[numero omesso]-9
License (as archived)
solo-consultazione
Archived
2026-11-08T07:00:56.954Z
SHA-256 of the archived text
0f0a3a68d0bdeead4ce8ba5a01c08d8f2f8294fb047ca45256605236d9e1fdf8
Stable URL of this page
https://metraipolis.com/documento/dc_109fe18092ef

How to cite

Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade — Europe PMC PMID:41291775 — Europe PMC (en), https://europepmc.org/article/MED/41291775 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_109fe18092ef (Metraipolis archive dc_109fe18092ef, sha256 0f0a3a68d0bdeead4ce8ba5a01c08d8f2f8294fb047ca45256605236d9e1fdf8)
BibTeX
@misc{dc109fe18092ef,
  title = {Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade — Europe PMC PMID:41291775},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41291775},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_109fe18092ef; sha256 0f0a3a68d0bdeead4ce8ba5a01c08d8f2f8294fb047ca45256605236d9e1fdf8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41291775. Agents can read the archived copy with the MCP tool read_document.